Lesson plan
WOBE437
WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research. It is a highly potent and selective endocannabinoid reuptake inhibitor, with an of 10 nM in terms of this action. The drug produces anxiolytic-like, anti-inflammatory, analgesic, antiallodynic, and muscle relaxant effects in rodents. These effects are mediated by increased endocannabinoid levels, including of anandamide (AEA) and 2-arachidonylglycerol (2-AG), and are dependent on cannabinoid receptors, for instance the cannabinoid CB 1 receptor. Conversely, WOBE437 did not produce catalepsy, affect locomotor activity, or produce the typical sedation of cannabinoid CB 1 receptor agonists. The drug also showed effectiveness in an animal model of multiple sclerosis. Originally believed to be selective, off-target activities of WOBE437 have subsequently been identified and described. WOBE437 is orally bioavailable in rodents. Numerous analogues of WOBE437 have been explored in search of candidates with better drug-like properties, though a series of almost 80 compounds found none that were more potent than WOBE437 itself. WOBE437 was first described in the scientific literature by 2013.
Article summary
WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research. It is a highly potent and selective endocannabinoid reuptake inhibitor, with an of 10 nM in terms of this action. The drug produces anxiolytic-like, anti-inflammatory, analgesic, antiallodynic, and muscle relaxant effects in rodents. These effects are mediated by increased endocannabinoid levels, including of anandamide (AEA) and 2-arachidonylglycerol (2-AG), and are dependent on cannabinoid receptors, for instance the cannabinoid CB 1 receptor. Conversely, WOBE437 did not produce catalepsy, affect locomotor activity, or produce the typical sedation of cannabinoid CB 1 receptor agonists. The drug also showed effectiveness in an animal model of multiple sclerosis. Originally believed to be selective, off-target activities of WOBE437 have subsequently been identified and described. WOBE437 is orally bioavailable in rodents. Numerous analogues of WOBE437 have been explored in search of candidates with better drug-like properties, though a series of almost 80 compounds found none that were more potent than WOBE437 itself. WOBE437 was first described in the scientific literature by 2013.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.